J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneider, D.
Right arrow Articles by DeFusco, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneider, D.
Right arrow Articles by DeFusco, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Influence of sucralfate on trilisate bioavailability

DK Schneider, RH Gannon, KR Sweeney, and PA DeFusco

Twelve healthy human volunteers were randomized to receive either choline-magnesium trisalicylate (CMT) 1.5 g orally every 12 hours or a combination of CMT plus sucralfate 1 g orally every 6 hours for 5 days before the blood sampling day. After a 3-week washout period, the subjects were crossed over to receive the alternate treatment for 5 days. The mean (+/- SD) area under the curve was 2668 (729) mg - hr/L and 2748 (716) mg - hr/L for CMT and CMT/sucralfate treatments, respectively. Mean (+/- SD) maximum concentration was 275 (69) mg/L and 283 (75) mg/L for CMT and CMT/sucralfate administrations, respectively. Mean (+/- SD) time to maximum concentration for CMT and CMT/sucralfate treatments was 1.8 (0.6) hours and 1.7 (0.7) hours, respectively. There were no significant differences detected for any parameter, therefore sucralfate does not affect rate or extent of CMT absorption.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American College of Clinical Pharmacology